Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.33 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20782639 | 0.91 | ALDH1A1 (0.40) | ALDH1A1LMNAALBMAPK1 | |
| SCHEMBL24060672 | 0.86 | ALDH1A1 (0.39) | ALDH1A1LMNAALBMAPK1 | |
| SCHEMBL20692011 | 0.83 | ALDH1A1 (0.37) | ALDH1A1LMNAALBMAPK1IMPDH2 | |
| SCHEMBL22340256 | 0.81 | ALDH1A1 (0.39) | ALDH1A1LMNAALBMAPK1IMPDH2 | |
| SCHEMBL20692222 | 0.80 | ALDH1A1 (0.32) | ALDH1A1LMNAALBMAPK1 | |
| SCHEMBL20927155 | 0.70 | BCHE (0.51) | ALDH1A1MAPK1 | |
| SCHEMBL22351987 | 0.70 | BCHE (0.51) | ALDH1A1MAPK1 | |
| SCHEMBL22340218 | 0.70 | IMPDH2 (0.44) | IMPDH2IMPDH1 | |
| SCHEMBL25808149 | 0.69 | HPGD (0.46) | IMPDH2IMPDH1 | |
| SCHEMBL22351932 | 0.68 | ALDH1A1 (0.48) | ALDH1A1LMNAALBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3658565-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-11-09 | — | — | EP | disclosed |
| WO-2019023459-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-31 | — | — | WO | disclosed |